Novo Nordisk Haemophilia A drug does well in Phase III trial


Novo Nordisk (NVO) "reports positive results" from the first Phase III trial of its N8-GP treatment for Haemophilia A.

The study assessed the safety and efficacy of N8-GP when administered for prophylaxis and when given on-demand in patients who are aged 12 and above.

Other than that, Novo provided no other information about the results. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs